K2 Health Ventures
May 23, 2019
The Business Cocktail
Merck decides to acquire Peloton Therapeutics, fortifying Oncology pipeline Merck is ready to buy Peloton Therapeutics for USD 1.1 million. The companies have entered into a definitive agreement which will give Merck rights over an oral HIF-2α inhibitor- PT2977, which is Peloton’s lead candidate for the treatme...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
